Venetoclax Combined With <scp>FLAG</scp>‐<scp>IDA</scp> in Refractory or Relapsed Acute Myeloid Leukemia
The FLAVIDA regimen represents a promising treatment alternative for R/R AML patients with a high response rate and significantly improved EFS compared to standard chemotherapy.
Authors
- Martin Grießhammer (ORCID: https://orcid.org/0000-0001-8718-7004)
- Kai Wille (ORCID: https://orcid.org/0000-0002-7682-8563)
- Vera Kolatzki
- Anette Horstmann
- Raphael Meixner
- Parvis Sadjadian (ORCID: https://orcid.org/0000-0002-6380-6840)
- Christiane Fuchs (ORCID: https://orcid.org/0000-0003-3565-8315)
- Marina Jiménez‐Muñoz (ORCID: https://orcid.org/0000-0002-4543-2929)
- Marvin Dumke
- Nadine Wilsdorf
- Stephanie Jender‐Bartling
- Artur Schneider
- Hans‐Joachim Tischler
Institutions
- Bielefeld University (DE)
- Helmholtz Zentrum München (DE)
- Johannes Wesling Klinikum Minden (DE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/ejh.14302
- Citations
- 9
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 4.09